November 6, 2026

@michaelokun

Could weight loss drugs also protect our brains? GLP-1 therapies, obesity and cognition. GLP-1 stands for glucagon-like peptide-1, a hormone that helps regulate blood sugar, appetite and metabolism. Drugs such as semaglutide mimic this hormone and are changing how we treat obesity and diabetes. But could they also change how we think, remember and age? Stina Börchers and colleagues describe in a new review in Science, part of the November 2026 special issue GLP-1 and Beyond, how obesity medications may influence cognition and brain health. The review explores whether these effects come from direct actions on brain circuits, improvements in metabolic health, or both. Key points: - GLP-1 therapies have been associated w/ lower rates of cognitive decline and dementia in some studies of folks w/ obesity and diabetes, but the evidence remains largely observational and results across clinical trials are mixed. - These medications may influence cognition through multiple pathways, including improved blood sugar regulation, vascular health, sleep and inflammation, as well as possible direct effects on brain cells and circuits. - Clinical trials in established Alzheimer's disease, including EVOKE and EVOKE+, have not demonstrated meaningful slowing of cognitive or functional decline, despite some encouraging changes in biomarkers. My take: This review resonated w/ me because it challenges us to think beyond weight loss and ask whether treating metabolic dysfunction could become part of our strategy for preserving brain health. The brain does not operate independently of the rest of the body. Obesity, diabetes, inflammation, vascular disease and sleep disorders all interact w/ brain function. However, we must resist the temptation to declare GLP-1 drugs the next breakthrough in dementia prevention before we have definitive evidence. The negative Alzheimer's trials are an important reminder that changing a biomarker is not the same as changing a patient's life.